Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option
- PMID: 15018591
- DOI: 10.2165/00003495-200464060-00004
Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option
Abstract
Symptomatic urinary tract infections (UTIs) are a major public health concern in the developed world, accounting for almost 8 million annual outpatient and emergency department visits in the US alone, while also representing one of the most common hospital-acquired infections. The vast majority of uncomplicated UTIs are caused by the Gram-negative bacillus Escherichia coli, with other pathogens including enterococci, Staphylococcus saprophyticus, Klebsiella spp. and Proteus mirabilis. Effective management of UTIs in both the inpatient and outpatient settings has been complicated by the fact that many uropathogenic strains have developed resistance to antimicrobials, including cotrimoxazole (trimethoprim/sulfamethoxazole), the current first-line treatment for uncomplicated UTIs in the US and many other countries. In some countries, other antimicrobial therapies, such as trimethoprim and nitrofurantoin, are also used for treatment of uncomplicated UTIs. Antimicrobial resistance has been associated with an increased rate of clinical failure, and reports from Canada and the US indicate that the prevalence of cotrimoxazole resistance exceeds 15% and can be as high as 25%.The emergence and dissemination of antimicrobial resistance can be reduced with the use of agents that have favourable pharmacokinetic/pharmacodynamic profiles and convenient dose administration regimens that facilitate patient adherence and, therefore, pathogen eradication. Fluoroquinolones have been used successfully to treat a wide range of community- and hospital-acquired infections, and the rates of fluoroquinolone resistance have remained low. Use of fluoroquinolones is recommended for uncomplicated UTIs in areas where the incidence of cotrimoxazole resistance exceeds 10%, as well as for the treatment of complicated UTIs and acute pyelonephritis. Ciprofloxacin is a widely used fluoroquinolone with high bactericidal activity against uropathogens and well established clinical efficacy in the treatment of UTIs. A new, extended-release formulation of ciprofloxacin (Cipro XR) provides systemic drug exposure comparable with that achieved with twice-daily administration of conventional, immediate-release ciprofloxacin, while also attaining higher maximum plasma concentrations with less interpatient variability. Therapeutic drug concentrations with extended-release ciprofloxacin are established immediately after dose administration and maintained throughout the 24-hour dosage interval, permitting convenient, once-daily treatment. Clinical trial results confirm that extended-release ciprofloxacin is as safely used and effective as the conventional, immediate-release formulation of ciprofloxacin in patients with uncomplicated UTIs, complicated UTIs or acute uncomplicated pyelonephritis. These findings support the use of extended-release ciprofloxacin as a well tolerated, effective and convenient therapy for UTIs, which may improve patients' adherence to therapy and, thereby, reduce the risk of infection recurrence and emergence of antimicrobial resistance.
Similar articles
-
Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections.Int J Antimicrob Agents. 2004 Mar;23 Suppl 1:S54-66. doi: 10.1016/j.ijantimicag.2003.12.005. Int J Antimicrob Agents. 2004. PMID: 15037329 Review.
-
Ciprofloxacin extended release: in the treatment of urinary tract infections and uncomplicated pyelonephritis.Drugs Aging. 2004;21(1):55-64; discussion 65-6. doi: 10.2165/00002512-200421010-00005. Drugs Aging. 2004. PMID: 14715044 Review.
-
The treatment of urinary tract infections and use of ciprofloxacin extended release.Expert Opin Investig Drugs. 2006 May;15(5):519-32. doi: 10.1517/13543784.15.5.519. Expert Opin Investig Drugs. 2006. PMID: 16634690 Review.
-
Role of fluoroquinolones in the treatment of serious bacterial urinary tract infections.Drugs. 2004;64(12):1359-73. doi: 10.2165/00003495-200464120-00007. Drugs. 2004. PMID: 15200349 Review.
-
Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.Clin Ther. 2002 Dec;24(12):2088-104. doi: 10.1016/s0149-2918(02)80099-6. Clin Ther. 2002. PMID: 12581547 Clinical Trial.
Cited by
-
Bacterial Profile And Antibiotic Susceptibility Pattern Of Urinary Tract Infection Among Children Attending Felege Hiwot Referral Hospital, Bahir Dar, Northwest Ethiopia.Infect Drug Resist. 2019 Nov 18;12:3575-3583. doi: 10.2147/IDR.S217574. eCollection 2019. Infect Drug Resist. 2019. PMID: 31819542 Free PMC article.
-
In vitro Effects of Antimicrobial Agents on Planktonic and Biofilm Forms of Staphylococcus saprophyticus Isolated From Patients With Urinary Tract Infections.Front Microbiol. 2019 Jan 28;10:40. doi: 10.3389/fmicb.2019.00040. eCollection 2019. Front Microbiol. 2019. PMID: 30745897 Free PMC article.
-
The potential impact of biomarker-guided triage decisions for patients with urinary tract infections.Infection. 2013 Aug;41(4):799-809. doi: 10.1007/s15010-013-0423-1. Epub 2013 Feb 24. Infection. 2013. PMID: 23435720
-
Effects of ibeA deletion on virulence and biofilm formation of avian pathogenic Escherichia coli.Infect Immun. 2011 Jan;79(1):279-87. doi: 10.1128/IAI.00821-10. Epub 2010 Oct 25. Infect Immun. 2011. PMID: 20974831 Free PMC article.
-
Suppression subtractive hybridization identifies an autotransporter adhesin gene of E. coli IMT5155 specifically associated with avian pathogenic Escherichia coli (APEC).BMC Microbiol. 2010 Sep 9;10:236. doi: 10.1186/1471-2180-10-236. BMC Microbiol. 2010. PMID: 20828376 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous